Literature DB >> 12700464

Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein.

Daesety Vishnuvardhan1, Lisa L Moltke, Clemens Richert, David J Greenblatt.   

Abstract

The effect of lopinavir on P-glycoprotein-mediated rhodamine 123 efflux was studied in Caco-2 monolayer cells. Lopinavir is a potent inhibitor of Rh123 efflux in Caco-2 monolayers (IC50 1.7 microM). Chronic lopinavir exposure (72 h) in LS 180V cells reduced the content of intracellular Rh123 by approximately 50%, indicating increased efflux activity. In LS 180V cells, lopinavir induced P-glycoprotein immunoreactive protein (up to threefold) and messenger RNA levels in a concentration-dependent fashion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700464     DOI: 10.1097/01.aids.0000060380.78202.b5

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  26 in total

Review 1.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 2.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

3.  Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.

Authors:  Tammy M Meyers; Marcel Yotebieng; Louise Kuhn; Harry Moultrie
Journal:  Pediatr Infect Dis J       Date:  2011-11       Impact factor: 2.129

4.  Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.

Authors:  Paolo Denti; Anneke C Hesseling; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Tjokosela Tikiso; Lubbe Wiesner; Mine de Kock; Jana Winckler; Jennifer Norman; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

Review 5.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

6.  Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.

Authors:  Laurence Bousquet; Alain Pruvost; Anne-Cécile Guyot; Robert Farinotti; Aloïse Mabondzo
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

7.  CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.

Authors:  F Josephson; L Bertilsson; Y Böttiger; L Flamholc; M Gisslén; V Ormaasen; A Sönnerborg; U Diczfalusy
Journal:  Eur J Clin Pharmacol       Date:  2008-05-06       Impact factor: 2.953

8.  Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.

Authors:  Alain Pruvost; Eugènia Negredo; Frédéric Théodoro; Jordi Puig; Mikaël Levi; Rafaela Ayen; Jacques Grassi; Bonaventura Clotet
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

9.  Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor.

Authors:  Sheetal Agarwal; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2007-03-06       Impact factor: 5.875

Review 10.  Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.

Authors:  Ankit Shah; Mohitkumar R Gangwani; Nitish S Chaudhari; Alexy Glazyrin; Hari K Bhat; Anil Kumar
Journal:  Neurotox Res       Date:  2016-06-30       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.